检索结果 - Peter Klare

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes

    Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes 由 Gerhard Schäller, Ilka Fuchs, Thomas Gonsch, Jan Weber, Anke Kleine-Tebbe, Peter Klare, Hans-Joachim Hindenburg, Volker Lakner, Axel Hinke, Nikola Bangemann

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

    Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology O... 由 Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik, Alain G. Zeimet, Harald Sommer, Peter Klare, Martina Stauch, A. Paulenz, Oumar Camara, E. Keil, W. Lichtenegger

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    The Impact of a Ten-Week Physical Exercise Program on Health-Related Quality of Life in Patients with Inflammatory Bowel Disease: A Prospective Randomized Controlled Trial

    The Impact of a Ten-Week Physical Exercise Program on Health-Related Quality of Life in Patients with Inflammatory Bowel Disease: A Prospective Randomized Controlled Trial 由 Peter Klare, Johanna Nigg, J Nold, Bernhard Haller, Anne Krug, Sebastian Mair, Christoph K. Thoeringer, Jeffrey W. Christle, Roland M. Schmid, Martin Halle, Wolfgang Huber

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) 由 Peter A. Fasching, Theresa Link, Jan Hauke, Fenja Seither, Christian Jackisch, Peter Klare, Sabine Schmatloch, Claus Hanusch, Jens Huober, Andrea Stefek, Sabine Seiler, Wolfgang Schmitt, Christoph Uleer, Gabriele Doering, Kerstin Rhiem, Andreas Schneeweiß, Knut Engels, Carsten Denkert, Rita K. Schmutzler, Eric Hahnen, Michael Untch, Nicole Burchardi, Jens‐Uwe Blohmer, Sibylle Loibl

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Role of<i>TP53</i>mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

    Role of<i>TP53</i>mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy 由 Silvia Darb‐Esfahani, Carsten Denkert, Albrecht Stenzinger, Christoph Salat, Bruno V. Sinn, Christian Schem, Volker Endris, Peter Klare, Wolfgang Schmitt, Jens‐Uwe Blohmer, Wilko Weichert, Markus Möbs, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Sherene Loi, Michael Untch, Gϋnter von Minckwitz, Valentina Nekljudova, Sibylle Loibl

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial

    Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant trea... 由 Andreas Schneeweiß, Volker Möbus, Hans Tesch, Claus Hanusch, Carsten Denkert, Kristina Lübbe, Jens Huober, Peter Klare, Sherko Kümmel, Michael Untch, Karin Kast, Christian Jackisch, Jörg Thomalla, Barbara Ingold‐Heppner, Jens‐Uwe Blohmer, Mahdi Rezai, Matthias Frank, Knut Engels, Kerstin Rhiem, Peter A. Fasching, Valentina Nekljudova, Gϋnter von Minckwitz, Sibylle Loibl

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

    Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto 由 Sibylle Loibl, Karsten E. Weber, Kirsten M. Timms, Eric P. Elkin, Eric Hahnen, Peter A. Fasching, Bianca Lederer, Carsten Denkert, Andreas Schneeweiß, Susanne Braun, Christoph Salat, Mahdi Rezai, Jens‐Uwe Blohmer, D-M. Zahm, Christian Jackisch, B. Gerber, Peter Klare, Sherko Kümmel, Christian Schem, Stefan Paepke, Rita K. Schmutzler, Kerstin Rhiem, Suzanna Penn, J. Reid, Valentina Nekljudova, A-R Hartman, Gϋnter von Minckwitz, Michael Untch

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary... 由 Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang Schmitt, Christian Schem, Karin Fisch, Silvia Darb‐Esfahani, Keyur Mehta, Christos Sotiriou, Stephan Wienert, Peter Klare, Fabrice André, Frederick Klauschen, Jens‐Uwe Blohmer, Kristin Krappmann, Marcus Schmidt, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Michael Untch, Sibylle Loibl

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology

    Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology 由 Zahra Dantes, Hsi-Yu Yen, Nicole Pfarr, Christof Winter, Katja Steiger, Alexander Muckenhuber, Alexander Hennig, Sebastian Lange, Thomas Engleitner, Rupert Öllinger, Roman Maresch, Felix Orben, Irina Heid, Georgios Kaissis, Kuangyu Shi, Geoffrey J. Topping, Fabian Stögbauer, Matthias Wirth, Katja Peschke, Aristeidis Papargyriou, Massoud Rezaee-Oghazi, Karin Feldmann, Arlett Schäfer, Raphela A. Ranjan, Clara Lubeseder–Martellato, Daniel E. Stange, Thilo Welsch, Marc E. Martignoni, Güralp O. Ceyhan, Helmut Frieß, Alexander Herner, Lucia Liotta, Matthias Treiber, Guido von Figura, Mohamed Abdelhafez, Peter Klare, Christoph Schlag, Hana Algül, Jens T. Siveke, Rickmer Braren, Gregor Weirich, Wilko Weichert, Dieter Saur, Roland Rad, Roland M. Schmid, Günter Schneider, Maximilian Reichert

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: